Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting

On May 19, 2021 Aadi Bioscience ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported the release of an abstract selected for poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Annual Meeting being held virtually on June 4-8, 2021 (Press release, Aadi, MAY 19, 2021, View Source [SID1234580332]). The poster presentation will highlight antitumor activity in a subset of patients with TSC1 or TSC2 alterations and neoplasms other than advanced malignant PEComa who were treated with single-agent nab-sirolimus (FYARRO) in an expanded access program (NCT03817515). Details on the abstract are summarized below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations
Abstract Number: 3111
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Session Date and Time: June 4, 2021 at 9 AM CT